Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Market Cap	9.94M 11.36M 9.17M 8.47M 16.06M 1.08B 16.33M 110M 43.01M 534M 42.66M 41.73M 1.83B	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	8.23M 9.41M 7.59M 7.01M 13.3M 897M 13.53M 90.69M 35.61M 442M 35.32M 34.56M 1.52B	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	30.7%	Yield 2024 *	-	Yield 2025	-

04-15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/09/25	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/09/25	Celyad Oncology announces research facility divestiture	RE
28/09/25	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/09/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/08/25	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/07/25	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
27/07/25	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/06/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/06/25	Celyad Oncology Announces Strategic Review	CI
02/04/25	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/02/25	Celyad: share price soars on encouraging data

28/02/22	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/01/22	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/08/21	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/03/21	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/12/20	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

05-20	Celyad Oncology : AGM Minutes - informal translation EN	PU
04-02	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/09/25	Celyad Oncology : Announces Research Facility Divestiture	PU
12/09/25	Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	AQ
11/09/25	Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	PU

05-20	Celyad Oncology : AGO Procès Verbal - version FR
04-17	Celyad Oncology : Rapport Annuel 2025 FR
04-17	Celyad Oncology : Statutory Annual Accounts 2025 FR
04-17	Celyad Oncology : Shareholder Proxy Legal Entities FR / EN
04-17	Celyad Oncology : Shareholder Proxy Natural Persons FR / EN

Celyad SA Share Price Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad SA

Latest news : Celyad SA

Analysts' recommendations: Celyad SA

Press Releases: Celyad SA

News in other languages: Celyad SA

Quotes and Performance

Managers and Directors: Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	31/12/2018
An Phan LAW	General Counsel	51	31/08/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	23/07/2007
Serge Goblet BRD	Director/Board Member	-	31/12/2007
Hilde Windels CHM	Chairman	61	22/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	11.36M
LONZA GROUP AG	+0.02%	+0.93%	+3.75%	+10.28%	50.73B
REVOLUTION MEDICINES, INC.	-2.68%	-2.78%	+381.40%	+596.25%	39.73B
IQVIA HOLDINGS INC.	+0.63%	+1.01%	+29.92%	-5.28%	34.69B
BEONE MEDICINES AG	+2.09%	-0.63%	+21.96%	+55.17%	33.21B
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+31.73%	26.76B
ASCENDIS PHARMA A/S	-2.55%	-0.75%	-	-	16.8B
MEDPACE HOLDINGS, INC.	-1.21%	-4.76%	+68.00%	+123.86%	15.37B
EUROFINS SCIENTIFIC SE	+0.29%	+0.67%	+14.96%	+16.75%	13.78B
ICON PUBLIC LIMITED COMPANY	-1.06%	-2.75%	+11.18%	-33.23%	12.85B
Average	-2.87%	-0.83%	+66.77%	+99.44%	27.1B
Weighted average by Cap.	-0.22%	-0.23%	+81.84%	+125.12%

	2024	2025
Net sales	186K 213K 172K 158K 301K 20.28M 306K 2.05M 805K 9.99M 798K 781K 34.35M	21K 24.01K 19.37K 17.89K 33.95K 2.29M 34.52K 231K 90.89K 1.13M 90.14K 88.18K 3.88M
Net income	-5.82M -6.66M -5.37M -4.96M -9.41M -635M -9.57M -64.18M -25.21M -313M -25M -24.46M -1.08B	830K 949K 766K 707K 1.34M 90.5M 1.36M 9.15M 3.59M 44.58M 3.56M 3.49M 153M
Net Debt	-3.3M -3.77M -3.04M -2.81M -5.33M -359M -5.42M -36.31M -14.26M -177M -14.14M -13.84M -608M	-1.71M -1.95M -1.58M -1.46M -2.76M -186M -2.81M -18.82M -7.39M -91.74M -7.33M -7.17M -315M